Loading

rescheduling

  • by Paul Armentano, NORML Deputy Director August 10, 2016

    imgresThe United States Drug Enforcement Administration has rejected a pair of administrative petitions that sought to initiate rulemaking proceedings to reschedule marijuana under federal law.

    Although the DEA’s ruling continues to classify marijuana in the same category as heroin, the agency also announced in a separate decision that it is adopting policy changes designed to expand the production of research-grade cannabis for FDA-approved clinical studies.

    Presently, any clinical trial involving cannabis must access source material cultivated at the University of Mississippi — a prohibition that is not in place for other controlled substances. Today, the agency announced for the first time that it will be seeking applications from multiple parties, including potentially from private entities, to produce marijuana for FDA-approved research protocols as well as for “commercial product development.” This change was initially recommended by the DEA’s own administrative law judge in 2007, but her decision was ultimately rejected by the agency in 2011.

    Below is a statement from NORML Deputy Director Paul Armentano regarding the DEA’s decisions:

    For far too long, federal regulations have made clinical investigations involving cannabis needlessly onerous and have placed unnecessary and arbitrary restrictions on marijuana that do not exist for other controlled substances, including some other schedule I controlled substances.

    While this announcement is a significant step toward better facilitating and expanding clinical investigations into cannabis’ therapeutic efficacy, ample scientific evidence already exists to remove cannabis from its schedule I classification and to acknowledge its relative safety compared to other scheduled substances, like opioids, and unscheduled substances, such as alcohol. Ultimately, the federal government ought to remove cannabis from the Controlled Substances Act altogether in a manner similar to alcohol and tobacco, thus providing states the power to establish their own marijuana regulatory policies free from federal intrusion.

    Since the DEA has failed to take such action, then it is incumbent that members of Congress act swiftly to amend cannabis’ criminal status in a way that comports with both public and scientific opinion. Failure to do so continues the federal government’s ‘Flat Earth’ position; it willfully ignores the well-established therapeutic properties associated with the plant and it ignores the laws in 26 states recognizing marijuana’s therapeutic efficacy.

    Under the U.S. Controlled Substances Act of 1970, the cannabis plant and its organic cannabinoids are classified as Schedule I prohibited substances — the most restrictive category available under the law. By definition, substances in this category must meet three specific inclusion criteria:

    The substance must possess “a high potential for abuse”; it must have “no currently accepted medical use” in the United States; and, the substance must lack “accepted safety for use … under medical supervision.”

    Substances that do not meet these criteria must, by law, be categorized in less restrictive federal schedules (Schedules II through V) and are legally regulated accordingly. Alcohol and tobacco, two substances widely acknowledged to possess far greater dangers to health than does cannabis, are not classified under the Controlled Substances Act.

    A recent review of FDA-approved clinical studies evaluating the safety and efficacy of herbal cannabis concluded: “Based on evidence currently available the Schedule I classification is not tenable; it is not accurate that cannabis has no medical value, or that Information on safety is lacking.”

    Added Armentano: “The DEA’s decision is strictly a political one. There is nothing scientific about willful ignorance.”

    The DEA has previously rejected several other rescheduling petitions, including a 2002 petition filed by a coalition of marijuana law reform and health advocacy organizations, and a 1972 petition filed by NORML. The petitions that triggered this latest DEA action were filed in 2009 by a nurse practitioner and in 2011 by then-Govs. Christine Gregoire of Washington and Lincoln Chafee of Rhode Island.

  • by Danielle Keane, NORML Associate July 22, 2016

    take_actionThe DEA announced that they will amend their quotas for 2017 regarding the cultivation of research-grade marijuana and hemp legalization bills in Pennsylvania and Rhode Island have been signed into law! We also have updates from Illinois, Florida, and Ohio. Keep reading to learn the latest in marijuana law reform news from around the country and to find out how you can #TakeAction!

    Federal:

    In a notice published in the Federal Register, Acting DEA Administrator Chuck Rosenberg proposed amending the amount of marijuana that may be produced under federal license in 2017 to approximately 1,041 pounds. The agency alleges that this quantity will be sufficient to provide for the “estimated medical, scientific, research and industrial needs of the United States.”

    The US Drug Enforcement Administration is also preparing to respond to an administrative petition calling for the reclassification of marijuana as a schedule I prohibited substance. Their determination was originally expected in the first half of 2016 but it has yet to be released.

    State:

    Florida: Next Tuesday, the state’s first state-licensed medical marijuana dispensary will open to the public. Trulieve, a licensed cannabis cultivator and distributor, will provide a high CBD, low THC strain of the plant to patients that are registered with the state. However, as of today not a single eligible patient is registered with the state to legally access the product. This is because Florida’s law, initially passed in 2014, is among the strictest in the country. Under the law, patients diagnosed with cancer, seizures, or intractable muscle spasms are eligible for CBD-dominant cannabis, while those diagnosed with a terminal illness are eligible for THC-dominant cannabis. To date, however, only 15 physicians in the state are participating in the program.

    Illinois: Two months ago lawmakers voted in favor of Senate Bill 2228, legislation to decriminalize the possession of small amounts of marijuana. But Governor Bruce Rauner has yet to sign the measure into law. The bill makes the possession of up to 10 grams of marijuana a civil violation punishable by a fine of $100-$200 — no arrest and no criminal record. Currently, those caught possessing that amount could face up to six months of jail time and fines of up to $1,500. The bill also amends the state’s zero tolerance per se traffic safety law.

    #TakeAction  and contact Governor Rauner to urge him to sign this legislation into law.

    Ohio: Governor John Kasich has signed legislation so that certain drug offenses are no longer punishable by a mandatory loss of one’s driver’s license. Under previous law, any drug conviction carried a mandatory driver’s license suspension of at least six months, even in cases where the possession offense did not take place in a vehicle. Senate Bill 204 makes such suspensions discretionary rather than mandatory. The law will take effect September 13th, 2016.

    industrial_hempPennsylvania: On Wednesday, July 20th, Governor Tom Wolf signed legislation, House Bill 967, to establish “a pilot program to study the growth, cultivation or marketing of industrial hemp.” The new law took immediate effect. Twenty-eight states have now enacted similar legislation.

    Rhode Island: Governor Gina Raimondo has signed legislation, H8232, to establish rules for the commercial, licensed cultivation of hemp in the state. The legislation creates the “Hemp Growth Act” to treat hemp as an agricultural product that may be legally produced, possessed, distributed and commercially traded. The Department of Business Regulation will be responsible for establishing rules and regulations for the licensing and regulation of hemp growers and processors.

  • by Danielle Keane, NORML Associate May 27, 2016

    take_actionFederal lawmakers pressured President Obama this week to take executive action to reform marijuana policy. Meanwhile, state legislative reforms are still moving forward throughout the country. Keep reading to get the latest news and to learn what you can do to take action.

    Federal:

    Fourteen members of the U.S. House of Representatives sent a letter this week to President Obama urging the administration to enact various marijuana law reforms.

    The letter requests the administration to reschedule marijuana under federal law to Schedule III or a lower category, or to deschedule it altogether; to license additional growers of cannabis for research purposes; to extend protections for secondary and tertiary businesses that serve the medical marijuana industry, and to ensure that the Justice Department better respects Congressionally-enacted legislation preventing it from interfering with well-regulated state medical cannabis programs.

    The letter comes after the Drug Enforcement Agency (DEA) announced recently that it will soon issue a decision on pending petitions seeking to reclassify marijuana. However, lawmakers cautioned that reclassification is only one of many changes needed with regard to federal marijuana regulations. The letter reads, “We would like to caution against adopting the assumption that rescheduling alone is the panacea to the difficulties currently facing businesses, practitioners, and consumers. As such, we implore your Administration to investigate additional reforms that may be made administratively.”

    State:

    legalization_pollCalifornia: The Public Policy Institute of California released new polling information Thursday showing “broad and increasing support for a legal, regulated system of adult-use marijuana in California.” The Adult Use of Marijuana Act (AUMA), which is expected to appear on the November ballot, permits adults to legally grow (up to six plants) and possess personal use quantities of cannabis (up to one ounce of flower and/or up to eight grams of concentrate) while also licensing commercial cannabis production and retail sales. The measure prohibits localities from taking actions to infringe upon adults’ ability to possession and cultivate cannabis for non-commercial purposes.

    Sixty-nine percent of Democrats, 65 percent of independents and 45 percent of Republicans support regulating the adult use of marijuana, according to the poll, In each demographic, support has increased in recent months. National NORML has endorsed the AUMA, along with California Lieutenant Governor Gavin Newsom, U.S. Reps. Ted Lieu and Dana Rohrabacher, the California Council of Land Trusts, the Drug Policy Alliance, the Marijuana Policy Project, the California Cannabis Industry Association, the California Medical Association, and the California NAACP.

    Ohio: Lawmakers in both chambers have approved legislation, House bill 523, to regulate the use of medical cannabis preparations by qualified patients. The bill authorizes the use of various forms of cannabis preparations for the physicians-authorized treatment of nearly two-dozen conditions, including chronic pain, epilepsy, and Crohn’s. It calls on the state to license the production, distribution, and testing of cannabis products. Home cultivation is not allowed. Products may be dispensed as oils, tinctures, edibles, patches, or as plant material. However, smoking herbal cannabis is not permitted under the measure. Vaporizing medical cannabis products is permitted. Similar restrictions exist in three other states: Minnesota, New York, and Pennsylvania.

    The measure now awaits action from Gov. John Kasich, who may be contacted here.

    Proponents seeking to place a separate, broader medical marijuana measure on the 2016 ballot announced on May 28 that they were suspending their campaign, stating, “[A]ll in all, it is a moderately good piece of legislation passed by lawmakers who were pushed hard by the patient community. We plan on continuing forward as an advocacy effort to ensure that the State of Ohio lives up to the promises contained in HB 523, but also working to better the program utilizing our amendment as a roadmap for those improvements.”

    thumbs_upPennsylvania: Representative Ed Gainey has introduced legislation, House Bill 2076, to amend the state’s controlled substances act so that minor marijuana possession offenses are considered a non-criminal offense. The legislation would impose a fine and a summary conviction for an individual possessing 30 grams or less of marijuana or eight grams or less of hashish. Offenders would no longer face criminal arrest, incarceration, or a criminal record. The bill is now pending before the House Judiciary committee. #TakeAction

    West Virginia: Legislation was recently introduced to decriminalize the possession and cultivation of limited quantities of marijuana in West Virginia.

    House Bill 114 permits the personal use, growth and possession of up to two ounces of marijuana by persons over the age of twenty-one who have acquired a “tax stamp” from the state. It removes marijuana from the state list of schedule I drugs and decriminalizes first-time marijuana distribution offenses involving under 30 grams of marijuana. Adults will be allowed to transfer to another person twenty-one years of age or older, without remuneration, one ounce or less of marijuana.

    Adults who choose to grow their own marijuana will be permitted to cultivate and harvest up to six pants. #TakeAction

  • by Paul Armentano, NORML Deputy Director April 6, 2016

    personal_cultivationA recent memorandum from the US Drug Enforcement Administration to several United States Senators indicates that the agency is prepared to respond in the coming months to a five-year-old petition seeking to amend the plant’s status as a schedule I prohibited substance.

    Under the US Controlled Substances Act of 1970, the cannabis plant and its organic cannabinoids are classified as schedule I prohibited substances — the most restrictive category available under the law. As summarized by the DEA, “Schedule I drugs are the most dangerous drugs of all the drug schedules with potentially severe psychological or physical dependence.”

    Explicitly, substances in this category must meet three specific inclusion criteria: The substance must possess “a high potential for abuse”; it must have “no currently accepted medical use” in the United States; and the substance must lack “accepted safety for use … under medical supervision.” Substances that do not meet these criteria must, by law, be categorized in less restrictive federal schedules (schedule II through schedule V) and are legally regulated accordingly. (For example, schedule II substances like morphine or methadone are available by prescription.) Alcohol and tobacco, two substances that possess far greater dangers to health than does cannabis, are not subject to federal classification under the CSA.

    Federal law grants power to the US Attorney General to reclassify a controlled substance if the available scientific evidence no longer supports that drug’s classification. In practice, however, this power has been delegated to the DEA, with input from both FDA and the US Department of Health and Human Services. Federal law also allows third parties to petition these agencies to consider reclassifying controlled substances.

    The petition now before the DEA was filed in 2011 by then-governors Christine Gregoire of Washington and Lincoln Chafee of Rhode Island. Other recent rescheduling petitions, such as a 2002 petition filed by a coalition of marijuana law reform and health advocacy organizations, have been rejected outright by the agency. In 1990, the DEA set aside the decision of its own administrative law judge, who had responded in 1988 to a petition effort initiated by NORML, after he called for reclassifying the plant.

    While it remains unknown at present time if the DEA will respond favorably to this current rescheduling effort, it has become apparent in recent years that reclassifying cannabis from schedule I to schedule II – the same category as cocaine – falls well short of the sort of federal reform necessary to reflect America’s emerging reefer reality. Specifically, reclassifying the pot plant from I to II (or even to schedule III) continues to misrepresent the plant’s safety relative to other controlled substances such as methamphetamine (schedule II), anabolic steroids (schedule III), or alcohol (unscheduled), and fails to provide states with the ability to fully regulate it free from federal interference.

    Further, the federal policies in place that make clinical trial work with cannabis more onerous than it is for other controlled substances — such as the requirement that all source material be purchased from NIDA’s University of Mississippi marijuana cultivation program — are regulatory requirements that are specific to cannabis, not to Schedule I drugs in general. Simply rescheduling cannabis from I to II does not necessarily change these regulations, at least in the short-term.

    In addition, the sort of gold-standard, large-scale, long-term Phase III safety and efficacy trials that are typically necessary prior to bringing therapeutic drugs to market are prohibitively expensive. As a result, trials of this kind are typically are funded by private pharmaceutical companies aspiring to bring a new product to market. In some cases, the federal government may assist in sharing these costs, such as was the case with the research and development of the synthetic THC pill Marinol (dronabinol). However, political reality dictates that neither entity is likely to pony up the tens of millions of dollars necessary to conduct such trials assessing the efficacy of herbal cannabis any time soon, if ever, regardless of the plant’s federal scheduling.

    This is not to say that rescheduling cannabis would not have any positive tangible effects. At a minimum, it would bring an end to the federal government’s longstanding intellectual dishonesty that marijuana ‘lacks accepted medical use.’ It would also likely permit banks and other financial institutions to work with state-compliant marijuana-related businesses, and permit employers in the cannabis industry to take tax deductions similar to those enjoyed by other businesses. Rescheduling would also likely bring some level of relief to federal employees subject to random workplace drug testing for off-the-job cannabis consumption.

    But ultimately, such a change would do little to significantly loosen federal prohibition or to make herbal cannabis readily accessible for clinical study. These goals can arguably only be accomplished by federally decsheduling cannabis in a manner similar to alcohol and tobacco, such as is proposed by US Senate Bill 2237, The Ending Federal Marijuana Prohibition Act. Doing so will finally provide states the power to establish their own marijuana policies free from federal intrusion.

  • by Paul Armentano, NORML Deputy Director October 29, 2015

    thumbs_upVermont Senator and Democrat Presidential candidate Bernie Sanders yesterday pledged to get the federal government out of the marijuana enforcement business by removing the substance from the US Controlled Substances Act.

    Senator Sanders called cannabis’ present schedule I status under federal law “absurd.” He added: “In my view, the time is long overdue for us to remove the federal prohibition on marijuana. … [S]tates should have the right to regulate marijuana the same way that state and local laws now govern the sale of alcohol and tobacco.”

    The Senator also said that state-compliant marijuana operations “should be fully able to use the banking system without fear of federal prosecution.”

    Senator Sanders comments differ from those of Democrat opponent and former Maryland Gov. Martin O’Malley who promised to use the executive powers of the President to “to move marijuana from Schedule I to Schedule II of the Controlled Substances Act.” Republican candidate Rand Paul [R-KY] has also co-sponsored federal legislation, SB 683, that seeks to reclassify cannabis to Schedule II under federal law. However, simply rescheduling marijuana from I to II would not limit the federal government’s authority to prosecute marijuana offenders, including those who are in compliance with state law.

    While several other Presidential candidates have called on federal officials to respect states’ marijuana policies, none have proposed amending federal marijuana laws.

    Senator Sanders latest position is consistent with the view of most voters. According to a 2015 Pew poll, 60 percent of Americans agree that the government “should not enforce federal marijuana laws in states that allow use,” while recent Gallup survey data finds that 58 percent of US citizens over the age of 18 believe cannabis should be legal for adults.

Page 1 of 212